Recombinant human interleukin-2
OptiLeukin™ 2
GMP Recombinant human interleukin-2 for T-cell, Treg, TIL, NK, and γδ T-cell expansion across research, process development, and cGMP cell therapy manufacturing.
| Option | Price |
|---|---|
| Closed-System Liquid (100k IU) | Contact Product Applications |
| Liquid Vial (1M IU) | Contact Product Applications |
| Lyophilized Powder Vial (100 μg) | Contact Product Applications |
Please contact the Product Applications Team at info@invitria.com
Composition
- Purity
- ≥97%
- Endotoxin
- ≤0.01 EU/µg
- Activity (ED50)
- Determined by proliferation of mouse CTLL-2 cells
- Formats
- Liquid, closed-system
Compliance
- Manufacturing
- cGMP, ISO 9001:2015
- Facility
- Junction City, KS
- Sterility
- Sterile Liquid
- Documentation
- Lot-specific CoA
Product overview
A recombinant IL-2 for immune cell expansion.
OptiLeukin™ 2 is recombinant human interleukin-2 for CAR-T, TIL, NK, Treg, and γδ T-cell expansion, from research through cGMP manufacturing. Whether your process calls for a powder, a ready-to-use liquid, or a fully closed system, there is a format to match. The lyophilized powder (555OLK0070) lets you reconstitute at the concentration your protocol requires, a flexible fit for research and process development. The liquid vial (777OLK108) arrives ready to use, removing the reconstitution step.
For closed manufacturing, the cGMP closed-system liquid (777OLK107) is designed to be welded directly into your process. That eliminates IL-2 and media syringe preparation under Grade A conditions and lets IL-2 be added directly in Grade C/D environments. With no lyophilized material to reconstitute and no open handling steps, contamination risk is reduced and the process becomes more robust. IL-2 can be delivered throughout the culture, the container evacuates completely so no material is left behind, and operators have fewer steps to manage.



Featured Resources
The published data behind the claims
Technical specifications
| Attribute | Value |
|---|---|
| Physical & Chemical | |
| Form | Liquid |
| Molecular weight | ~15.5 kDa |
| Purity | ≥97% |
| Endotoxin level | ≤0.01 EU/µg |
| Activity (ED50) | ED50 ≤1 ng/mL as determined by proliferation of mouse CTLL-2 cells |
| Size/Amount | 100,000 IU (closed-system liquid), 1M IU (liquid vial), 100 µg (lyophilized vial) |
| Sterility | Sterile Liquid |
| Shelf life | 9 months from DOM (liquid) w/ ongoing stability study |
| Storage conditions | 2 to 8 °C |
| Composition | |
| Product name | OptiLeukin™ 2 |
| Brand | InVitria® |
| SKU / Product Number | 777OLK108 liquid vial · 777OLK107 closed-system format |
| Protein | Recombinant Human Interleukin-2 (rhIL-2) |
| Class | Cytokine / Interleukin |
| Synonyms | IL-2, rhIL-2 |
| Status | Recombinant, Animal-Origin Free |
| Carrier protein / stabilizer | None (no additives or preservatives) |
| Regulatory | |
| Production standard | ISO 9001:2015, cGMP-compliant facility |
| Country of origin | USA (Junction City, KS) |
| Documentation | Certificate of Analysis (request form) · Data Sheet · Guidelines for Use · Certificate of Origin and Animal-Free / TSE-BSE Statement · ISO 9001:2015 certificate · cGMP Statement · product-specific Technical Summary on request |
Key Benefits
- Low Endotoxin Specification
- OptiLeukin™ 2 is released at ≤0.01 EU/µg endotoxin.
- Matches a GMP Competitor IL-2
- Day 10 T cell expansion matched a GMP IL-2 for two lots and two donors.
- Formats for every stage
- A liquid vial (777OLK108) for process development and a closed-system format (777OLK107) for closed-loop CAR-T, TIL, NK, Treg, and γδ T-cell manufacturing.
- High Purity, Carrier-Free
- Closed-system format: ≥97% purity, sterile, mycoplasma-negative, with no carrier protein or stabilizer.
How to order OptiLeukin™ 2
- Catalog purchase
- OptiLeukin 2 is supplied by quote. Both formats are quoted through the request form: the liquid vial (777OLK108) for process development, and the closed-system format (777OLK107) for cGMP manufacturing.
- Purchase Order
- Contact info@invitria.com or a Product Applications team member at InVitria to submit a PO directly.
- Bulk pricing
- Bulk and custom packaging is available to support cell therapy process development and clinical manufacturing. Working directly with InVitria gives access to bulk and commercial-scale supply, volume-tier pricing, and GMP supply commitments. Start with a bulk pricing request.
- Regional distribution
- OptiLeukin 2 is available worldwide through multiple purchasing pathways, including distributors through the Find a Distributor request. It is also available through Fisher Scientific, VWR, and the Labviva procurement platform. European customers can order with direct fulfillment from InVitria’s Rotterdam, Netherlands facility.
A Certificate of Analysis is issued for every lot and is available through the request form. The Data Sheet, Guidelines for Use, ISO 9001:2015 certificate, and cGMP Statement are published resources. TSE/BSE statement and Certificate of Origin are published resources. A product-specific Technical Summary is available on request.
Common questions
OptiLeukin 2 is a recombinant human interleukin-2 (rhIL-2) produced on InVitria’s ExpressTec™ expression platform, a non-bacterial, non-mammalian, animal-origin-free expression system. It is available in two formats; a liquid vial (777OLK108), and a liquid closed-system format (777OLK107). The closed-system cGMP format delivers ≥97% purity, ≤0.01 EU/µg endotoxin, and ED50 ≤1 ng/mL activity as determined by proliferation of mouse CTLL-2 cells, supporting T-cell, Treg, TIL, NK, and γδ T-cell expansion workflows across research, process development, and clinical manufacturing.
OptiLeukin 2 is produced recombinantly on InVitria’s ExpressTec expression platform, a rice-based expression system with no animal-derived, human-derived, or blood-derived materials. It is manufactured without animal-derived components in raw materials, processing aids, or manufacturing equipment, which supports ICH compliance and simplifies adventitious agent qualification for cell therapy, gene therapy, and immunotherapy regulatory submissions.
OptiLeukin-2 is released at ≥97% purity, ≤0.01 EU/µg endotoxin, ED50 ≤1 ng/mL activity as determined by proliferation of mouse CTLL-2 cells, sterile, mycoplasma-negative, and with identity confirmed against the reference standard. Every lot is released with full Certificate of Analysis documentation covering purity, endotoxin, activity, identity, sterility, mycoplasma, pH, protein concentration, and host cell protein content.
Yes. OptiLeukin 2 is manufactured under an ISO 9001:2015-certified, cGMP-compliant quality management system. The product is 100% animal-origin-free. Raw materials, the recombinant protein expression platform, manufacturing equipment, and product-contact packaging are all free of animal-derived components.
OptiLeukin 2 is supported by a Certificate of Analysis, Safety Data Sheet, Guidelines for Use, application notes describing immune cell expansion performance, Certificate of Origin and Animal-Free / TSE-BSE Statement, ISO 9001 certificate, and cGMP Statement. Additional quality and regulatory documentation is available on request, including materials for IND-supporting packages and supplier qualification.
Yes. OptiLeukin 2 aligns with ICH Q5A guidance on viral safety evaluation of biotechnology products derived from cell lines. The absence of animal-derived and human-derived source materials reduces the adventitious agent qualification burden, which simplifies CMC documentation for biopharmaceutical, cell therapy, and gene therapy programs.
Yes. An open DMF for OptiLeukin 2 is available upon request.
Yes. InVitria’s application note Sustained T Cell Proliferation and Early Memory Retention with OptiLeukin 2 Recombinant IL-2 documents sustained T-cell proliferation and retention of favorable early memory-associated phenotypes (Tscm, Tcm) under defined expansion conditions. These results support its use in cell therapy manufacturing programs where maintaining a less differentiated T-cell phenotype is a critical process attribute directly associated with improved CAR-T cell persistence and clinical durability. In the study, phenotypes were mostly Tscm on day 4 and a roughly equal split of Tscm, Tcm, Tem, and Temra by day 9, with little difference between OptiLeukin 2 and the GMP competitor IL-2 within a given donor, timepoint, and dose.
InVitria’s application note documents OptiLeukin 2 performance comparable to a leading GMP IL-2 product for T-cell proliferation and phenotype. Day 10 cumulative fold expansion showed no significant difference among IL-2 treated groups across two donors and two OptiLeukin 2 lots. The comparability data supports evaluation of OptiLeukin 2 for programs seeking an animal-origin-free raw material, a low endotoxin specification (≤0.01 EU/µg), and the closed-system format for cGMP cell therapy manufacturing workflows.
The liquid vial format (777OLK108) supports process development and scale-up workflows where a ready-to-use liquid simplifies workflow integration. The closed-system format (777OLK107) is the cGMP-grade offering for closed-loop CAR-T, TIL, NK, Treg, and γδ T-cell manufacturing workflows where sterile, mycoplasma-negative, regulatory-ready raw materials are required. Contact InVitria to discuss the best format for a specific application.
Yes. OptiLeukin 2 is designed for expansion workflows across CAR-T, TIL, Treg, NK, and γδ T-cell manufacturing programs. The closed-system cGMP format integrates into closed-loop cell therapy manufacturing processes where sterile, chemically defined raw materials are required, while the animal-origin-free expression system and ≤0.01 EU/µg endotoxin specification support raw material qualification for IND/BLA-stage cell therapy programs.
OptiLeukin 2 is designed for expansion workflows involving T cells, Tregs, TILs, NK cells, and γδ T cells in cell therapy development and manufacturing, including autologous CAR-T manufacturing, allogeneic off-the-shelf NK and γδ T-cell programs, regulatory T-cell therapies for autoimmune disease, TIL therapies for solid tumor indications, and iPSC-derived immune cell differentiation platforms. The defined, animal-origin-free composition supports chemically defined media systems across all of these applications.
The Guidelines for Use provide a typical stock concentration range and recommend optimizing the working dose by cell type, activation method, and culture density. Working concentrations are typically bracketed during process development to balance proliferation rate and phenotype outcomes, particularly in CAR-T and Treg workflows where maintaining less-differentiated phenotypes is a critical process attribute. InVitria’s application note tested 5, 20, and 60 ng/mL, equivalent to 50, 200, and 600 IU/mL of the NIBSC 1st International Standard IL-2, and saw a mild dose dependence with more differentiated phenotypes at higher doses.
OptiLeukin 2 is compatible with common basal media used in T-cell, NK-cell, Treg, and TIL expansion workflows, including, but not limited to, RPMI 1640, OpTmizer Suite, X-VIVO 15, AIM V, and proprietary serum-free and chemically defined formulations. It is typically added directly to basal medium at the empirically determined working concentration as part of a complete defined or serum-free expansion formulation.
OptiLeukin 2 is available worldwide through multiple purchasing pathways. Most customers work directly with InVitria for full access to the OptiLeukin 2 portfolio, bulk and commercial-scale supply, favorable volume-tier pricing, faster supply chain turnaround, GMP supply commitments, and regulatory documentation support. OptiLeukin 2 is also available through Fisher Scientific, VWR, and the Labviva procurement platform, which integrates with Ariba, Coupa, Oracle, and Jaggaer, for customers whose institutional procurement systems require integrated supplier ordering. European customers can order with direct fulfillment from InVitria’s Rotterdam, Netherlands facility. All customers receive the same product, Certificate of Analysis, and technical support regardless of channel. Contact InVitria or request bulk pricing to place an order.
Store OptiLeukin 2 in liquid format at 2 to 8 °C, per the Guidelines for Use and the product Certificate of Analysis.
Use the Certificate of Analysis request form. A Certificate of Analysis is issued for every lot.
OptiLeukin™ 2 is built for these applications
Talk to Product Applications
Discuss your specific cell therapy workflow.
InVitria’s Product Applications scientists are available to talk through cell type, activation method, working concentration, format, and scale.